Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7570983rdf:typepubmed:Citationlld:pubmed
pubmed-article:7570983lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:7570983lifeskim:mentionsumls-concept:C1704256lld:lifeskim
pubmed-article:7570983lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:7570983lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:7570983lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:7570983lifeskim:mentionsumls-concept:C1515406lld:lifeskim
pubmed-article:7570983lifeskim:mentionsumls-concept:C0851285lld:lifeskim
pubmed-article:7570983pubmed:issue7lld:pubmed
pubmed-article:7570983pubmed:dateCreated1995-11-22lld:pubmed
pubmed-article:7570983pubmed:abstractTextScarring, fibrosis, and immunosuppression occurs with chronic cyclosporine (CsA) administration. We postulated that CsA may induce transforming growth factor (TGF)-beta 1 secretion from human T lymphocytes, a cytokine with immunoregulatory effects that has been implicated in the pathogenesis of wound healing and scarring. TGF-beta 1 was measured in serum-free supernatants harvested from T lymphocytes stimulated in the presence of CsA by a specific sandwich ELISA. CsA (10-1000 ng/ml) enhanced TGF-beta 1 secretion by approximately 40-80% in a dose-dependent manner. Increased TGF-beta 1 secretion in the presence of CsA was accompanied by a 2- to 4-fold increase in TGF-beta 1 mRNA levels due to both enhancement of its nuclear transcription as well as prolongation of TGF-beta 1 mRNA half-life. To determine whether the increase in TGF-beta 1 secretion was also accompanied by a concomitant change in its receptor, TGF-beta 1 receptor expression was analyzed by cross-linking of radioiodinated TGF-beta 1. Unactivated T lymphocytes expressed both a 105-kDa and a 65-kDa TGF-beta receptor. Upon stimulation, a transient increase in receptor density was seen at 12 hr, followed by a decline at later time points. Cells treated with CsA exhibited at least 2-fold higher levels of TGF-beta receptors in a dose-dependent manner. Thus, CsA enhances the production of TGF-beta 1 protein as well as the expression of its receptor in activated T lymphocytes. Enhanced TGF-beta 1 production and binding may contribute to the immunosuppressive and fibrosis-promoting effects of CsA therapy.lld:pubmed
pubmed-article:7570983pubmed:languageenglld:pubmed
pubmed-article:7570983pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7570983pubmed:citationSubsetIMlld:pubmed
pubmed-article:7570983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7570983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7570983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7570983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7570983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7570983pubmed:statusMEDLINElld:pubmed
pubmed-article:7570983pubmed:monthOctlld:pubmed
pubmed-article:7570983pubmed:issn0041-1337lld:pubmed
pubmed-article:7570983pubmed:authorpubmed-author:BalowJ EJElld:pubmed
pubmed-article:7570983pubmed:authorpubmed-author:AhujaS SSSlld:pubmed
pubmed-article:7570983pubmed:authorpubmed-author:DanielpourDDlld:pubmed
pubmed-article:7570983pubmed:authorpubmed-author:BoumpasD TDTlld:pubmed
pubmed-article:7570983pubmed:authorpubmed-author:ShrivastavSSlld:pubmed
pubmed-article:7570983pubmed:issnTypePrintlld:pubmed
pubmed-article:7570983pubmed:day15lld:pubmed
pubmed-article:7570983pubmed:volume60lld:pubmed
pubmed-article:7570983pubmed:ownerNLMlld:pubmed
pubmed-article:7570983pubmed:authorsCompleteYlld:pubmed
pubmed-article:7570983pubmed:pagination718-23lld:pubmed
pubmed-article:7570983pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:meshHeadingpubmed-meshheading:7570983-...lld:pubmed
pubmed-article:7570983pubmed:year1995lld:pubmed
pubmed-article:7570983pubmed:articleTitleRegulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes.lld:pubmed
pubmed-article:7570983pubmed:affiliationKidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.lld:pubmed
pubmed-article:7570983pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7570983lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7570983lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7570983lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7570983lld:pubmed